


Gadodiamide hydrate

| | |
|---------------------------|--|
| Cat. No.: | HY-B0266 |
| CAS No.: | 122795-43-1 |
| Molecular Formula: | C ₁₆ H ₂₈ GdN ₅ O ₉ |
| Molecular Weight: | 591.67 |
| Target: | Biochemical Assay Reagents |
| Pathway: | Others |
| Storage: | 4°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light) |



SOLVENT & SOLUBILITY

In Vitro

H₂O : 100 mg/mL (169.01 mM; Need ultrasonic)
DMSO : 50 mg/mL (84.51 mM; Need ultrasonic)

| Preparing Stock Solutions | Solvent Concentration | Mass | 1 mg | 5 mg | 10 mg |
|---------------------------|--------------------------|---------------|-----------|-----------|------------|
| | | Concentration | 1 mg | 5 mg | 10 mg |
| | 1 mM | | 1.6901 mL | 8.4507 mL | 16.9013 mL |
| | 5 mM | | 0.3380 mL | 1.6901 mL | 3.3803 mL |
| | 10 mM | | 0.1690 mL | 0.8451 mL | 1.6901 mL |

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

Gadodiamide hydrate is a gadolinium-based contrast agent used in MR imaging procedures to assist in the visualization of blood vessels. Target: Others Gadodiamide hydrate is a gadolinium-based contrast agent used in MR imaging procedures to assist in the visualization of blood vessels. Gadodiamide hydrate is a contrast medium for cranial and spinal magnetic resonance imaging (MRI) and for general MRI of the body after intravenous administration. The product provides contrast enhancement and facilitates visualisation of abnormal structures or lesions in various parts of the body including the central nervous system (CNS). A recent review takes the question of toxicity caused by loss of gadolinium from the complex. "The challenge for nephrologists includes (a) evidence of transmetallation, such as gadolinium deposits in bone, increased urinary zinc excretion, iron-transferrin dissociation or 'spurious hypocalcemia' in exposed people" [1].

CUSTOMER VALIDATION

- Magn Reson Imaging. 2018 Oct 12;55:140-144.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Canavese, C., et al., Gadolinium-associated nephrogenic systemic fibrosis: the need for nephrologists' awareness. J Nephrol, 2008. 21(3): p. 324-36.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA